Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range (Q45211941)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 August 2012

Language	Label	Description	Also known as
English	Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range	scientific article published on 18 August 2012

Statements

scholarly article

1 reference

Europe PubMed Central

10 December 2017

Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range (English)

1 reference

Europe PubMed Central

10 December 2017

author name string

Kazuto Ito

1

1 reference

Europe PubMed Central

10 December 2017

Mai Miyakubo

2

1 reference

Europe PubMed Central

10 December 2017

Yoshitaka Sekine

3

1 reference

Europe PubMed Central

10 December 2017

Hidekazu Koike

4

1 reference

Europe PubMed Central

10 December 2017

Hiroshi Matsui

5

1 reference

Europe PubMed Central

10 December 2017

Yasuhiro Shibata

6

1 reference

Europe PubMed Central

10 December 2017

Kazuhiro Suzuki

7

1 reference

Europe PubMed Central

10 December 2017

publication date

18 August 2012

1 reference

Europe PubMed Central

10 December 2017

World Journal of Urology

1 reference

Europe PubMed Central

10 December 2017

31

1 reference

Europe PubMed Central

10 December 2017

2

1 reference

Europe PubMed Central

10 December 2017

305-311

1 reference

Europe PubMed Central

10 December 2017

https://scigraph.springernature.com/pub.10.1007/s00345-012-0927-9

0 references

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

A (-5, -7) proPSA based artificial neural network to detect prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

Volume determinations by transrectal ultrasonography in patients with benign prostatic hyperplasia: correlation with removed prostate weight.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

Prostate volume estimation using the ellipsoid formula consistently underestimates actual gland size.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0927-9

21 January 2018

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22903772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario

1 reference

https://pubmed.ncbi.nlm.nih.gov/22903772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1-10.0 ng/mL

1 reference

https://pubmed.ncbi.nlm.nih.gov/22903772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age

1 reference

https://pubmed.ncbi.nlm.nih.gov/22903772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pre-analytical in-vitro stability of [-2]proPSA in blood and serum

1 reference

https://pubmed.ncbi.nlm.nih.gov/22903772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of prostate volume by transrectal ultrasound

1 reference

https://pubmed.ncbi.nlm.nih.gov/22903772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22903772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00345-012-0927-9

1 reference

Europe PubMed Central

10 December 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45211941&oldid=2111881718"